Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

FDA Grants Orphan Drug Designation to MT-401 for AML

The FDA has granted orphan drug designation to MT-401, an allogeneic T-cell therapy for the treatment of acute myeloid leukemia (AML). MT-401, from Marker Therapeutics,...
WIB_icon

Prophylaxis Does Not Fully Prevent VTE Risk in Patients With ALL Treated With Asparaginase

Antithrombin (AT) replacement and heparin prophylaxis was not entirely effective for the prevention of venous thromboembolism (VTE) in adult patients with acute lymphocytic leukemia...

FDA Approves Investigative New Drug Application for AUTO1 CAR-T Therapy for ALL

The FDA has accepted the Investigational New Drug (IND) application of CD19-targeting chimeric antigen receptor (CAR) T-cell therapy AUTO1 for the treatment of adults...

FDA Grants CC-486 (Oral Azacitidine) Priority Review for AML Maintenance

The FDA granted priority review status to CC-486 for maintenance treatment of adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR)...

UGT1A1*28 Genotype Is Associated With Reduced Overall Survival in Intermediate-Risk AML

Patients with intermediate-risk acute myeloid leukemia (AML) who are treated with cytarabine-based chemotherapy have lower overall survival (OS) if they possess the low-activity UGT1A1*28...

First Human Trial of Off-the-Shelf CAR T-Cell Therapy Shows Promise

Last month at the virtual annual meeting of the American Association for Cancer Research (AACR), Chinese researchers announced results from the first human trial...
On location

MLL Associated With Worse Post-Transplant Outcomes Than Other Cytogenetic Factors

In an analysis comparing the effects of MLL translocations with other cytogenetic characteristics on post-transplant outcomes in acute myeloid leukemia (AML), investigators found that...

Venetoclax Plus High-Dose Cytarabine With or Without Idarubicin Well Tolerated in Pediatric AML

In a small study of children and young adults with relapsed or refractory acute myeloid leukemia (AML), venetoclax plus cytarabine chemotherapy, with or without...

Putting Mutation Testing in Myeloid Malignancies to the Test

In 2014, the World Health Organization (WHO) convened a clinical advisory committee to begin updating and revising the existing classification of myeloid neoplasms (MPNs)...

Emerging Opportunities: Reevaluating Maintenance Therapy in AML

The concept of maintenance therapy in acute myeloid leukemia (AML) is not new. But for decades, research was unable to show any clear survival...
Advertisement

Current Issue

July 2020 Volume 6 Issue 8

This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.